Table 5 Correlation analysis results from a general linear model with change from baseline to week 12 in CMV or EBV viral load or change in CRP level as the response variable, and dose of tofacitinib and change in lymphocyte sub-populations as explanatory variables
Change in response variables | Explanatory variables | ||||||
|---|---|---|---|---|---|---|---|
Dose of tofacitiniba | Lymphocyte sub-populations | ||||||
T (CD3+) | TH(CD3+/CD4+) | TC(CD3+/CD8+) | B (CD19+) | NK (CD16+/CD56+) | |||
CMV viral load, copies/500 ng total DNA | df | 3 | 1 | 1 | 1 | 1 | 1 |
F value | 1.26 | 0.14 | 0.04 | 0.68 | 0.00 | 0.03 | |
p value | 0.2926 | 0.7047 | 0.8411 | 0.4112 | 0.9925 | 0.8592 | |
EBV viral load, copies/500 ng total DNA | df | 3 | 1 | 1 | 1 | 1 | 1 |
F value | 0.50 | 0.54 | 1.69 | 0.11 | 0.02 | 0.57 | |
p value | 0.6807 | 0.4627 | 0.1955 | 0.7430 | 0.8906 | 0.4501 | |
CRP level, mg/L | df | 3 | 1 | 1 | 1 | 1 | 1 |
F value | 3.18 | 1.45 | 1.84 | 4.18 | 0.11 | 1.83 | |
p value | 0.0262 | 0.2315 | 0.1775 | 0.0430 | 0.7450 | 0.1784 | |